目的 探討疏血通注射液聯(lián)合桂哌齊特治療短暫性腦缺血發(fā)作的臨床療效。方法 選取2014年1月-2016年1月延安市人民醫(yī)院收治的短暫性腦缺血發(fā)作患者132例，隨機(jī)分為對(duì)照組和治療組，每組各66例。對(duì)照組靜脈滴注馬來酸桂哌齊特注射液，320 mg加入生理鹽水500 mL，1次/d；治療組在對(duì)照組的基礎(chǔ)上靜脈滴注疏血通注射液，6 mL加入生理鹽水250 mL，1次/d。兩組均連續(xù)治療14 d。觀察兩組患者的臨床療效，同時(shí)比較兩組治療前后血漿黏滯度（CP）、血細(xì)胞比容（HCT）、纖維蛋白原（FIB）、血小板聚集率（PAR）和ABCD評(píng)分的變化情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為83.33%、93.94%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組CP、HCT、FIB和PAR顯著降低，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)降低程度比對(duì)照組更明顯，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組ABCD評(píng)分顯著低于對(duì)照組，且其改善值優(yōu)于對(duì)照組，兩組ABCD評(píng)分變化比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 疏血通注射液聯(lián)合桂哌齊特治療短暫性腦缺血發(fā)作具有較好的臨床療效，可有效改善患者血液流變學(xué)相關(guān)指標(biāo)，降低早期發(fā)生腦梗死的風(fēng)險(xiǎn)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Shuxuetong Injection combined with cinepazide in treatment of transient ischemic attack. Methods Patients (132 cases) with transient ischemic attack in Yan'an People's Hospital from January 2014 to January 2016 were randomly divided into control and treatment groups, and each group had 66 cases. The patients in the control group were iv administered with Cinepazide Maleate Injection, 320 mg added into normal saline 500 mL, once daily. The patients in the treatment group were iv administered with Shuxuetong Injection on the basis of the control group, 6 mL added into normal saline 250 mL, once daily. The patients in two groups were treated for 14 d. After treatment, the efficacy was evaluated, and CP, HCT, FIB, PAR, and ABCD scores in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 83.33% and 93.94%, respectively, and there were differences between two groups (P<0.05). After treatment, the indexes of CP, HCT, FIB, and PAR in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the decrease degree of these observational indexes in the treatment group was more significant than that in the control group, with significant difference between two groups (P<0.05). After treatment, ABCD scores and it's improvement in the treatment group were obviously better than those in the control group, and there were differences between two groups (P<0.05). Conclusion Shuxuetong Injection combined with cinepazide has a good clinical efficacy in treatment of transient ischemic attack, which can effectively improve blood rheology indexes and reduce the risk of early cerebral infarction, which has a certain clinical application value.